CDHH (CDH13) Human siRNA Oligo Duplex (Locus ID 1012)
CAT#: SR300727
CDH13 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each
Need single siRNA in bulk?
Get a free quote
CNY 4,090.00
货期*
4周
规格
Cited in 1 publication. |
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
经常一起买 (3)
Anti-CDH13 (H Cadherin) mouse monoclonal antibody, clone OTI3H6 (formerly 3H6)
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Purity | HPLC purified |
Quality Control | Tested by ESI-MS |
Sequences | Available with shipment |
Stability | One year from date of shipment when stored at -20°C. |
# of transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
Note | Single siRNA duplex (10nmol) can be ordered. |
Reference Data | |
RefSeq | NM_001220488, NM_001220489, NM_001220490, NM_001220491, NM_001220492, NM_001257 |
Synonyms | CDHH; P105 |
Components | CDH13 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 1012)Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmolIncluded - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml |
Summary | This gene encodes a member of the cadherin superfamily. The encoded protein is localized to the surface of the cell membrane and is anchored by a GPI moiety, rather than by a transmembrane domain. The protein lacks the cytoplasmic domain characteristic of other cadherins, and so is not thought to be a cell-cell adhesion glycoprotein. This protein acts as a negative regulator of axon growth during neural differentiation. It also protects vascular endothelial cells from apoptosis due to oxidative stress, and is associated with resistance to atherosclerosis. The gene is hypermethylated in many types of cancer. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, May 2011] |
Performance Guranteed | OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency. For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer
,Zhang, D;Park, D;Zhong, Y;Lu, Y;Rycaj, K;Gong, S;Chen, X;Liu, X;Chao, HP;Whitney, P;Calhoun-Davis, T;Takata, Y;Shen, J;Iyer, VR;Tang, DG;,
Nat Commun
,PubMed ID 26924072
[CDH13]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...